(function(){
			var content_array=["<p><strong>About Janssen R&amp;D Ireland<\/strong><\/p>\r\n<p>At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases, and cardiovascular and metabolic diseases.<\/p>\r\n<p>We are further committed to making a meaningful difference in global public health. Inspired by the legacy of Dr. Paul Janssen and our commitment to patients, we work passionately to discover and responsibly deliver innovative medicines and vaccines that address serious unmet health needs, including HIV, tuberculosis, intestinal worms and neglected tropical diseases.<\/p>\r\n<p>We collaborate with members of the global healthcare community, including the Bill and Melinda Gates Foundation, the Global TB Alliance, the Drugs for Neglected Diseases Initiative, the International Partnership for Microbicides, and many others, to bring new solutions that deliver years of life and quality of life for people around the world.<\/p>\r\n<p>Janssen R&amp;D Ireland is part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. Please visit <a rel=\"nofollow\" href=\"http:\/\/www.janssenrnd.com\/\" target=\"_blank\"><strong>http:\/\/www.janssenrnd.com<\/strong><\/a> for more information.<\/p>\r\n<p style=\"text-align: center;\">##<\/p>\r\n<p><em>(This press release contains \"forward-looking statements\" as defined in the Private Securities Litigation Reform Act of 1995.<\/em> <em>The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.<\/em> <em>If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen R&amp;D Ireland, any of the other Janssen Pharmaceutical Companies and\/or Johnson &amp; Johnson.<\/em> <em>Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies.<\/em> <em>A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson &amp; Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.<\/em> <em>Copies of this Form 10-K, as well as subsequent filings, are available online at <\/em><a rel=\"nofollow\" href=\"http:\/\/www.sec.gov\/\" target=\"_blank\"><strong><em><\/em><\/strong><\/a><strong><em><a rel=\"nofollow\" href=\"http:\/\/www.sec.gov\" target=\"_blank\"><a rel=\"nofollow\" href=\"http:\/\/www.sec.gov\" target='_blank'>http:\/\/www.sec.gov<\/a><\/a><\/em><\/strong><em>, <\/em><a rel=\"nofollow\" href=\"http:\/\/www.jnj.com\/\" target=\"_blank\"><strong><em>http:\/\/www.jnj.com<\/em><\/strong><\/a> <em>or on request from Johnson &amp; Johnson. None of the Janssen Pharmaceutical Companies nor Johnson &amp; Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)<\/em><\/p>"];
			$("#dvExtra").html(content_array[0]);})();